Following last month’s dismissal of the securities class action complaint against Illumina Inc. and its former spinoff company, GRAIL, the plaintiffs have refiled an amended complaint, keeping the action alive.
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
The federal government shutdown is entering its fifth week, and funding delays are now directly affecting the healthcare system.
Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report, often called “the voice of the CDC,” now has an rival publication.
Last week, President Donald Trump announced a deal with pharmaceutical company Merck KGaA and its U.S. subsidiary, EMD Serono, to sharply reduce the cost of some fertility drugs used for in-vitro fertilization, in exchange for a three-year reprieve on some of the tariffs levied on pharmaceutical imports (The Cancer Letter, Oct. 24, 2025).
Jonathan D. Licht was named president and chief scientific officer of the Van Andel Institute. Licht will begin his new role in early 2026.
The University of Illinois College of Medicine and Cook County Health have expanded their collaborative partnership that began in 2021.
Vinai GondiBridget KoontzPriya RastogiLisa LenrowNRG Oncology, an NCI National Clinical Trials Network group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced changes in leadership across multiple committees.
Eytan Ruppin, a data scientist who works with AI-based methods for predicting individual patients’ response to cancer therapies, has joined Cedars-Sinai Cancer as deputy director of the Translational Research Institute. He will also serve as director of Integrative Data Sciences in the Division of Surgical Research.
The University of Texas MD Anderson Cancer Center has awarded Kimberly Vanderhorst and Terri Lynn Dunn the 2025 Brown Foundation Award for Excellence in Oncology Nursing.
